medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2019, Número 2

<< Anterior Siguiente >>

Rev Invest Clin 2019; 71 (2)


The Metabolomics Signature Associated with Responsiveness to Steroid Therapy in Focal Segmental Glomerulosclerosis: A Pilot Study

Chashmniam S, Kalantari S, Nafar M, Boroumandnia N

Idioma: Ingles.
Referencias bibliográficas: 37
Paginas: 106-115
Archivo PDF: 655.86 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Meyrier A. Mechanisms of disease: focal segmental glomerulosclerosis. Nat Clin Pract Nephrol. 2005;1:44-54.

  2. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol. 2004;15:2169-77.

  3. Korbet SM. Treatment of primary FSGS in adults. J Am Soc Nephrol. 2012;23:1769-76.

  4. D’Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365:2398-411.

  5. Uwaezuoke SN. The role of novel biomarkers in childhood idiopathic nephrotic syndrome: a narrative review of published evidence. Int J Nephrol Renovasc Dis. 2017;10:123-8.

  6. Gupta V, Reiser J. MicroRNAs: a macroview into focal segmental glomerulosclerosis. Am J Kidney Dis. 2015;65:206-8.

  7. Beaudreuil S, Lorenzo HK, Elias M, et al. Optimal management of primary focal segmental glomerulosclerosis in adults. Int J Nephrol Renovasc Dis. 2017;10:97-107.

  8. Beer A, Mayer G, Kronbichler A. Treatment strategies of adult primary focal segmental glomerulosclerosis: a systematic review focusing on the last two decades. BioMed Res Int. 2016;2016:9.

  9. Meyrier A. An update on the treatment options for focal segmental glomerulosclerosis. Expert Opin Pharmacother. 2009; 10:615-28.

  10. Banfi G, Moriggi M, Sabadini E, et al. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol. 1991; 36:53-9.

  11. Neuhaus TJ, Fay J, Dillon MJ, Trompeter RS, Barratt TM. Alternative treatment to corticosteroids in steroid sensitive idiopathic nephrotic syndrome. Arch Dis Child. 1994;71:522-6.

  12. Zhang A, Sun H, Yan G, Wang P, Wang X. Metabolomics for biomarker discovery: moving to the clinic. BioMed Res Int. 2015;2015:6.

  13. Wishart DS. Metabolomics: the principles and potential applications to transplantation. Am J Transplant. 2005;5: 2814-20.

  14. Blydt-Hansen TD, Sharma A, Gibson IW, Mandal R, Wishart DS. Urinary metabolomics for noninvasive detection of borderline and acute T cell-mediated rejection in children after kidney transplantation. Am J Transplant. 2014;14: 2339-49.

  15. Kalantari S, Nafar M, Rutishauser D, et al. Predictive urinary biomarkers for steroid-resistant and steroid-sensitive focal segmental glomerulosclerosis using high resolution mass spectrometry and multivariate statistical analysis. BMC Nephrol. 2014;15:141.

  16. Kalantari S, Nafar M, Samavat S, et al. 1H NMR-based metabolomics exploring urinary biomarkers correlated with proteinuria in focal segmental glomerulosclerosis: a pilot study. Magn Reson Chem. 2016;54:821-6.

  17. Viant MR. Improved methods for the acquisition and interpretation of NMR metabolomic data. Biochem Biophys Res Commun. 2003;310:943-8.

  18. Kamburov A, Cavill R, Ebbels TM, Herwig R, Keun HC. Integrated pathway-level analysis of transcriptomics and metabolomics data with IMPaLA. Bioinformatics. 2011;27:2917-8.

  19. Booth SC, Weljie AM, Turner RJ. Computational tools for the secondary analysis of metabolomics experiments. Comput Struct Biotechnol J. 2013;4:e201301003.

  20. Dennis G Jr., Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4:P3.

  21. Bonifačić D, Aralica M, Sotošek Tokmadžić V, et al. Values of vanillylmandelic acid and homovanillic acid in the urine as potential prognostic biomarkers in ischaemic stroke patients. Biomarkers. 2017;22:790-7.

  22. Koller WC, Melamed E. Handbook of Clinical Neurology: parkinson’s Disease and Related Disorders; Part I, II. Edinburgh: Elsevier; 2007.

  23. Farrant M, Webster R. Neurotransmitters, Drugs and Brain Function. England: John Wiley and Sons West Sussex; 2001.

  24. Sharma K, Karl B, Mathew AV, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol. 2013;24:1901-12.

  25. Kopple JD. Phenylalanine and tyrosine metabolism in chronic kidney failure. J Nutr. 2007;137:1586S-90S.

  26. Zbroch E, Koc-Zorawska E, Malyszko J, Malyszko J, Mysliwiec M. Circulating levels of renalase, norepinephrine, and dopamine in dialysis patients. Ren Fail. 2013;35:673-9.

  27. Zhang MZ, Yao B, Yang S, et al. Intrarenal dopamine inhibits progression of diabetic nephropathy. Diabetes. 2012;61: 2575-84.

  28. Park YH, Fitzpatrick AM, Medriano CA, Jones DP. High-resolution metabolomics to identify urine biomarkers in corticosteroid- resistant asthmatic children. J Allergy Clin Immunol. 2017;139:1518-240000.

  29. Endlich N, Endlich K. CAMP pathway in podocytes. Microsc Res Tech. 2002;57:228-31.

  30. Ding WY, Saleem MA. Current concepts of the podocyte in nephrotic syndrome. Kidney Res Clin Pract. 2012;31:87-93.

  31. Gruver-Yates AL, Cidlowski JA. Tissue-specific actions of glucocorticoids on apoptosis: a double-edged sword. Cells. 2013;2:202-23.

  32. Ryu JS, Ko JH, Kim MK, Wee WR, Oh JY. Prednisolone induces apoptosis in corneal epithelial cells through the intrinsic pathway. Sci Rep. 2017;7:4135.

  33. Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci. 2006;63: 60-72.

  34. Schmidt M, Pauels HG, Lügering N, et al. Glucocorticoids induce apoptosis in human monocytes: potential role of IL-1 beta. J Immunol. 1999;163:3484-90.

  35. Wada T, Pippin JW, Marshall CB, Griffin SV, Shankland SJ. Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and bcl-2-related family proteins. J Am Soc Nephrol. 2005;16:2615-25.

  36. Xing K, Gu B, Zhang P, Wu X. Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy. BMC Immunol. 2015;16:39.

  37. Kiffel J, Rahimzada Y, Trachtman H. Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients. Adv Chronic Kidney Dis. 2011;18:332-8.




2020     |     www.medigraphic.com